Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Surgical Oncology

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    670 result(s) found for: Surgical Oncology. Displaying page 1 of 34.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-000509-96 Sponsor Protocol Number: NL71166.041.19 Start Date*: 2020-05-14
    Sponsor Name:Princess Maxima Center for pediatric oncology
    Full Title: Near-infrared fluorescence imaging using indocyanine green as an adjunct to improve standard-of-care sentinel lymph node procedure in pediatric patients with melanoma or sarcoma of head/neck/trunk,...
    Medical condition: Sentinel node procedure for pediatric patients with melanoma or sarcoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000988-25 Sponsor Protocol Number: version4 Start Date*: 2012-04-27
    Sponsor Name:Gateshead Health NHS Trust Research & Development
    Full Title: To determine the feasibility of using Microbubble technology to detect sentinel nodes in vulvar cancer.
    Medical condition: Early stage vulvar cancer with no clinial or radiological evidence of lymph node metastases
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-002698-65 Sponsor Protocol Number: 05_DOG13_71 Start Date*: 2006-04-10
    Sponsor Name:Christie Hospital NHS Trust
    Full Title: A randomised clinical trial comparing safety and efficacy of topical preparations for the eradication of methicillin resistant staphylococcus aureus (MRSA) compared with a novel preparation based o...
    Medical condition: Colonisation with methicillin resistant Staphylococcus Aureus (MRSA)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004800-20 Sponsor Protocol Number: MK-3475-937 Start Date*: 2019-08-22
    Sponsor Name:Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete ...
    Medical condition: Adjuvant treatment of HCC
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) NO (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) BE (Ongoing) DK (Trial now transitioned) FR (Ongoing) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Ongoing) BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001371-38 Sponsor Protocol Number: EMR 62202-688 Start Date*: 2006-08-31
    Sponsor Name:Institute of Oncology Ljubljana
    Full Title: Cetuximab (Erbitux®), capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer: A phase II Pilot Study
    Medical condition: Locally advanced, resectable stage II/III rectal cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: View results
    EudraCT Number: 2004-002429-37 Sponsor Protocol Number: NSGO-EC-9501 Amendment 2 Start Date*: 2004-11-17
    Sponsor Name:Nordic Society for Gynecologic Oncology
    Full Title: A randomized trial of adjuvant treatment with radiation plus chemotherapy versus radiation alone in high-risk endometrial carcinoma NSGO-EC-9501 Amendment 2.
    Medical condition: Endometrial cancer stage I-III radically operated with high-risk factors (high-grade and deep myometrial infiltration, or serous or clear cell histology) that will receive adjuvant treatment with r...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001469-34 Sponsor Protocol Number: NEO-CESQ Start Date*: 2020-10-20
    Sponsor Name:FONDAZIONE MELANOMA ONLUS
    Full Title: A phase II, single arm study investigating neoadjuvant plus adjuvant treatment with Cemiplimab in high risk, surgically resectable, stage III Cutaneaous Squamous Cell Carcinoma
    Medical condition: high risk, surgically resectable, stage III Cutaneous Squamous Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041834 Squamous cell carcinoma of skin PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000782-21 Sponsor Protocol Number: VHIO19001 Start Date*: 2019-06-25
    Sponsor Name:Vall d' Hebron Institute of Oncology (VHIO)
    Full Title: Phase II Study of Avelumab plus chemotherapy in the peri-operative treatment for patients with resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC) – MONEO Study
    Medical condition: Resectable Gastric cancer (GC) or Gastroesphageal Junction cancer (GEJC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003007-35 Sponsor Protocol Number: R2810-ONC-1901 Start Date*: 2020-02-04
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC)
    Medical condition: Stage II to IV cutaneous squamous cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041823 Squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-001049-42 Sponsor Protocol Number: Start Date*: 2012-07-05
    Sponsor Name:Department of Oncology, Rigshospitalet
    Full Title: MRI-perfusion and FLT- and FET-PET during bevacizumab monotherapy for patients with recurrent Glioblastoma Multiforme
    Medical condition: Recurrent Glioblastoma multiforme
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-001270-28 Sponsor Protocol Number: Protokół_ASAPOL_wersja4_z_dnia_27_0 Start Date*: 2012-09-21
    Sponsor Name:Medical Centre of Postgraduate Education, Poland
    Full Title: The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Continuing or Discontinuing on Aspirin: a Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial
    Medical condition: Bleeding after removal large colorectal polyps in patients taking aspirin in profilactic doses or placebo
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-012260-14 Sponsor Protocol Number: 20050418 Start Date*: 2010-08-27
    Sponsor Name:Department of Endocrine Oncology
    Full Title: An open, non-randomized phase-2 study of efficacy and safety of treatment with 177Lutetium-DOTA0-Tyr3-octreotate in patients with neuroendocrine tumors
    Medical condition: Patients with malignant neuroendocrine tumours, not amenable to surgical treatment or radiofrequency ablation. Renal, bone marrow and liver function must be sufficient.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001071-37 Sponsor Protocol Number: LUC19-001 Start Date*: 2019-08-06
    Sponsor Name:Cliniques Universitaires Saint-Luc
    Full Title: Open label, phase II, Proof of Concept study of neoadjuvant celecoxib in newly diagnosed patients with endometrial carcinoma Acronym: Celebrido
    Medical condition: Patients with confirmed primary endometrioid adenocarcinoma eligible for first line curative surgery
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-013128-22 Sponsor Protocol Number: HE 42/09 Start Date*: 2010-06-29
    Sponsor Name:Hellenic Cooperative Oncology Group
    Full Title: Lapatinib and Whole Brain Radiotherapy for patients with brain metastases from lung and breast tumors. A phase II study of the Hellenic Cooperative Oncology Group (HeCOG).
    Medical condition: Patients with brain metastases from lung and breast tumors
    Disease: Version SOC Term Classification Code Term Level
    12.0 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2019-004796-40 Sponsor Protocol Number: 2018_58 Start Date*: 2020-06-11
    Sponsor Name:CHU de Lille
    Full Title: Multicenter Phase II study with dose-light escalation, intraoperative glioblastoma photodynamic therapy
    Medical condition: Glioblastoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004518-32 Sponsor Protocol Number: ITIC2-2.3 Start Date*: 2013-02-13
    Sponsor Name:Medizinische Universität Wien
    Full Title: ITIC2 Trial - Topical Imiquimod versus Conization to Treat Cervical Intraepithelial Neoplasia: Randomised Controlled, Non-inferiority Trial
    Medical condition: In this randomized controlled, multi-center trial we will investigate the non-inferiority of a topical IMQ treatment compared to surgical standard treatment in selected patients diagnosed with CIN ...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-005603-25 Sponsor Protocol Number: WO29636 Start Date*: 2015-07-30
    Sponsor Name:Roche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd.
    Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) VERSUS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH PD-L1-SELECTED, HIGH RISK MUSCLE INVASIVE BLADDER C...
    Medical condition: Muscle-invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10022877 Invasive bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FI (Completed) CZ (Completed) DE (Completed) BE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) FR (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2022-002586-15 Sponsor Protocol Number: SOGUG-2020-IEC(VEJ)-11 Start Date*: 2023-03-07
    Sponsor Name:Spanish Oncology Genito Urinary Group (SOGUG)
    Full Title: A Phase 2, open-label, multi-centre, multi-national interventional trial to evaluate the efficacy and safety of erdafitinib (ERDA) monotherapy and erdafitinib (ERDA) and cetrelimab (CET) combinatio...
    Medical condition: Muscle-invasive bladder cancer (MIBC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005081-17 Sponsor Protocol Number: ARV-471-BC-201 Start Date*: 2023-01-20
    Sponsor Name:Arvinas Estrogen Receptor, Inc. (Arvinas)
    Full Title: An Open-Label, Randomized, Non-Comparative Phase 2 Study of ARV-471 or Anastrozole in Post-Menopausal Women With ER+/HER2– Breast Cancer in the Neoadjuvant Setting
    Medical condition: Post-menopausal women with ER+ HER2– breast cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002814-38 Sponsor Protocol Number: SP005 Start Date*: 2013-09-27
    Sponsor Name:SOTIO a.s.
    Full Title: A Randomized, Double Blind, Multicenter, Parallel-group, Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer elig...
    Medical condition: metastatic castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) GB (Completed) DE (Completed) BE (Completed) CZ (Completed) IT (Completed) NL (Completed) ES (Completed) HU (Completed) PT (Completed) BG (Completed) SK (Completed) PL (Completed) HR (Completed) AT (Completed) LV (Completed) LT (Completed) DK (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:20:47 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA